Replies to post #10508 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

The diagram in #msg-29022959 comes from a slide GTC has used at investor webcasts, but I’m not sure if it still being used.

>I don't recall any reference to "CABG-COG = Cognitive deficit following coronary bypass" in anything from the company.<

That’s true—on recent CC’s, GTC has referred to CABG generally without specifying whether the indication is CABG-HR or CABG-COG. For instance, #msg-27446643 about halfway down:

>>
…we've also encouraged partners to look at the…additional opportunity of being able to develop ATryn in other acquired deficiency indications. At this moment, of course, Leo is paying entirely for the phase-2 [DIC] study which we'll get access to. So, the interesting thing for us is the possibility of being able to pursue, through a partner, other indications, and we've done work in the past in coronary artery bypass surgery and that's certainly an area which we continue to look at as a possible area of further clinical development and that could also, if we are able to secure a partner in the way in which we're working to at this moment, that could put us into a clinical development program which we would expect our partner to pay for and could bring us into the market more quickly than DIC itself in an acquired deficiency.
<<